Compare UFPI & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UFPI | RYTM |
|---|---|---|
| Founded | 1955 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Forest Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 5.9B |
| IPO Year | 2011 | 2017 |
| Metric | UFPI | RYTM |
|---|---|---|
| Price | $96.67 | $86.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 14 |
| Target Price | $102.50 | ★ $131.14 |
| AVG Volume (30 Days) | 346.6K | ★ 921.3K |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.46% | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ 5.00 | N/A |
| Revenue | ★ $3,941,182,000.00 | N/A |
| Revenue This Year | $2.04 | $54.90 |
| Revenue Next Year | $5.61 | $86.58 |
| P/E Ratio | $19.24 | ★ N/A |
| Revenue Growth | ★ 21.62 | N/A |
| 52 Week Low | $84.82 | $55.31 |
| 52 Week High | $118.00 | $122.20 |
| Indicator | UFPI | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 58.30 | 49.38 |
| Support Level | $88.09 | $84.39 |
| Resistance Level | $107.70 | $93.51 |
| Average True Range (ATR) | 2.33 | 4.20 |
| MACD | 1.25 | 0.85 |
| Stochastic Oscillator | 92.38 | 78.12 |
UFP Industries Inc is a supplier of lumber to the manufactured housing industry. Today UFP Industries is a multibillion-dollar holding company with subsidiaries around the globe that serve three markets: retail, packaging and construction. Its business segments consist of UFP Retail Solutions, UFP Packaging, UFP Construction, All other and Corporate. It describes itself as an innovation company, a logistics company, a design company, an engineering and value-added product and solutions company.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.